Targeted Complements: Exploring New Horizons Designed to address Gaps in Treating Complement-Mediated Kidney Disease

Thursday, December 29, 2022, 8:00 AM - Thursday, December 28, 2023, 11:59 PM

AMA PRA Category 1 Credits™ (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)


Explore new horizons in complement-targeted treatments with two leading experts who share fresh insights into the underlying pathophysiology of complement-associated kidney diseases and provide evidence-based guidance on their diagnosis and treatment.

There are no fees for participating in and receiving CME credit for this online activity. 

To view this activity, click here, or visit the content tab.

1. Explain the pathophysiology of complement-mediated kidney diseases, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets.
2. Differentially diagnose patients with complement- mediated kidney diseases in a timely manner, using evidence-based tools and strategies
3. Describe current and emerging treatments for complement-mediated kidney diseases, including data from recent clinical trials

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

All relevant relationships have been mitigated. The following disclosures were made:

Medical Director & Program Planners
PVI, PeerView Institute for Medical Education

Angela McIntosh, PhD, Medical Director 
Margery Tamas, MPH, Medical Director

PeerView staff do not have any relationships to report.

University of Cincinnati Center for Continuous Professional Development/CME

Bruce Gebhardt, MD, Physician Reviewer
Susan P. Tyler, PhD, Director, Continuing Medical Education
Heather Muskopf, Program Manager
Amy Spegal, Program Coordinator 

University of Cincinnati staff do not have any relationships to report.

Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24-months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education, or whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

FACULTY DISCLOSURES

Gerald Appel, MD, PhD, Chair
Professor of Medicine
Co-Director, Center for Glomerular Disease
Columbia University Irving Medical Center
New York, New York

Gerald Appel, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Apellis Pharmaceuticals; Arrowhead Pharmaceuticals, Inc.; Aurinia Pharmaceuticals Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Omeros Corporation; Pfizer; Reata Pharmaceuticals, Inc.; Sanofi; and Travere Therapeutics, Inc.
Grant/Research Support from Apellis Pharmaceuticals; Equillium, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Goldfinch Bio, Inc.; Mallinckrodt; Novartis Pharmaceuticals Corporation; Reata Pharmaceuticals, Inc.; Sanofi; and Travere Therapeutics, Inc.
Speakers Bureau participant with Aurinia Pharmaceuticals Inc. and GSK.

Andrew S. Bomback, MD, Presenter
Associate Professor of Medicine
Co-Director, Center for Glomerular Diseases
Columbia University Irving Medical Center
New York, New York

Andrew S. Bomback, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Apellis Pharmaceuticals; ChemoCentryx, Inc.; and Novartis Pharmaceuticals Corporation.

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.